Ironwood (IRWD) Reports Positive Data On Reflux Candidate
Zacks Investment Research | Jul 20, 2017 11:56PM ET
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) announced positive top-line data from a phase IIb study evaluating its gastrointestinal (GI) candidate, IW-3718, for the treatment of uncontrolled gastroesophageal reflux disease (GERD) in adult patients.
The study met its primary endpoint. The results demonstrated that an oral dose of IW-3718 (1500 mg) administered twice daily in combination with a proton pump inhibitor (PPI) significantly reduced heartburn severity (HS) in patients when compared to PPI alone.
However, investors didn’t seem to be impressed with the outcome. The clinical benefit shown by IW-3718 versus PPI alone was below expectations, which probably pulled the stock down by more than 8% on Thursday.
A look at its share price movement shows that the stock has outperformed the Original post
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.